Topic: Government Payers

  • Medicare Part B Premium Dynamics Explained

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs

  • Medicare Must Study Unproven, Expensive Alzheimer’s Drug

  • After 4 Years of Trump, Medicare and Medicaid Badly Need Attention

  • CMS’s Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs

  • Modeling P-quad

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • Fact Checking the NYT Fact Check on the Trump Proposal

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection